Navigation Links
AnaptysBio Announces New Strategic Antibody Discovery

SAN DIEGO, Jan. 6, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company.    The strategic alliance announced today with Novartis is AnaptysBio's second collaboration with the Swiss-based pharmaceutical company and follows an initial partnership where AnaptysBio successfully delivered antibody candidates for Novartis' development pipeline. 


Under the terms of each alliance, AnaptysBio will utilize its proprietary SHM-XEL platform for the discovery and maturation of novel therapeutic antibodies to multiple oncology-related therapeutic targets.  Each pharmaceutical partner will receive worldwide rights to develop and commercialize a limited number of antibodies against each therapeutic target generated by AnaptysBio.   In addition to an upfront payment and resource-based compensation, AnaptysBio is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from these alliances.

AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, functionality, cross-reactivity and epitope diversity.  The use of mammalian cell display permits AnaptysBio to optimize manufacturing-related parameters by selecting for high-level expression and stability in parallel.  Simultaneous secretion of antibody variants by the mammalian cells utilized during SHM-XEL also permits incorporation of functional assays in the antibody discovery process.   Key hallmarks of the SHM-XEL platform were recently published by AnaptysBio in Proceedings of the National Academy of Sciences (PNAS (2011), 108, 20455-20460).

"Our technology platform provides an integrated approach to antibody discovery using the natural biochemistry of somatic hypermutation in the context of mammalian cells," said Hamza Suria, president and chief executive officer for AnaptysBio. "We will continue to generate differentiated therapeutic candidates for our internal pipeline and under strategic alliances with select pharmaceutical partners."

About AnaptysBio

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies. The Company's SHM-XEL platform couples SHM with mammalian cell display to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection under controlled conditions – a process that has been referred to as "naturalizing" antibodies. This versatile platform can be used for both discovery of new antibodies and optimization of existing antibodies to generate candidates with desired properties for therapeutic applications. AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates. Major investors in AnaptysBio include founding investor Avalon Ventures, as well as Alloy Ventures, Frazier Healthcare Ventures, and Novo A/S. For more information, visit


Julie Rathbun


SOURCE AnaptysBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
2. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
3. AtheroNova Announces a New Board Member
4. RSB Spine, LLC Announces 2011 Revenue Growth
5. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
6. Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference
7. Verify Brand™ Announces the Release of VB Enterprise 4.0
8. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
9. NeoStem Announces Participation in Multiple January Conferences
10. Bionovo Announces $5 Million Financing
11. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
Post Your Comments:
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing ... AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... SUNNYVALE, Calif. , Nov. 24, 2015 ... executives will be speaking at the following conference, and ... New York, NY      Tuesday, December 1, ... New York, NY      Tuesday, December 1, ...      Piper Jaffray Healthcare Conference, New York, NY ...
Breaking Biology Technology:
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
(Date:11/17/2015)... , November 17, 2015 Paris ...   --> Paris from 17 th ... DERMALOG, the biometrics innovation leader, has invented the first combined ... on the same scanning surface. Until now two different scanners ... one scanner can capture both on the same surface. ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):